Alnylam Pharmaceuticals Inc (ALNY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has a cash flow conversion efficiency ratio of 0.207x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($163.56 Million) by net assets ($789.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View ALNY stock price and chart for real-time trading data and today's change.
Alnylam Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see Alnylam Pharmaceuticals Inc market capitalisation for the company's overall valuation and market capitalisation.
Alnylam Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Alnylam Pharmaceuticals Inc total assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Carnival Corporation
NYSE:CCL
|
0.097x |
|
KB Financial Group Inc
F:KBIA
|
0.122x |
|
Honda Motor Co Ltd ADR
NYSE:HMC
|
0.024x |
|
SUMITOMO CORP. SP. ADR 1
F:SUMB
|
N/A |
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-B
|
0.077x |
|
Telefonaktiebolaget LM Ericsson (publ)
F:ERCA
|
0.077x |
|
Ingersoll Rand Inc
NYSE:IR
|
0.035x |
|
Oil & Natural Gas Corporation Limited
NSE:ONGC
|
0.148x |
Annual Cash Flow Conversion Efficiency for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alnylam Pharmaceuticals Inc from 2002 to 2025. Review financial flexibility index of Alnylam Pharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $789.18 Million | $524.08 Million | 0.664x | +636.00% |
| 2024-12-31 | $67.09 Million | $-8.31 Million | -0.124x | +73.75% |
| 2023-12-31 | $-220.64 Million | $104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | $-158.22 Million | $-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | $588.20 Million | $-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | $1.02 Billion | $-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | $1.44 Billion | $-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | $1.30 Billion | $-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | $1.77 Billion | $-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | $920.22 Million | $-307.70 Million | -0.334x | -123.59% |
| 2015-12-31 | $1.26 Billion | $-189.14 Million | -0.150x | +15.47% |
| 2014-12-31 | $936.27 Million | $-165.64 Million | -0.177x | +30.34% |
| 2013-12-31 | $270.35 Million | $-68.66 Million | -0.254x | +70.55% |
| 2012-12-31 | $134.05 Million | $-115.61 Million | -0.862x | -16.88% |
| 2011-12-31 | $118.00 Million | $-87.07 Million | -0.738x | -38.44% |
| 2010-12-31 | $158.23 Million | $-84.34 Million | -0.533x | -31.48% |
| 2009-12-31 | $177.97 Million | $-72.14 Million | -0.405x | -225.12% |
| 2008-12-31 | $202.12 Million | $65.49 Million | 0.324x | -67.16% |
| 2007-12-31 | $199.17 Million | $196.52 Million | 0.987x | +905.92% |
| 2006-12-31 | $201.17 Million | $-24.63 Million | -0.122x | +54.12% |
| 2005-12-31 | $61.78 Million | $-16.48 Million | -0.267x | +37.09% |
| 2004-12-31 | $46.14 Million | $-19.57 Million | -0.424x | -188.30% |
| 2003-12-31 | $-26.71 Million | $-12.83 Million | 0.480x | +74.62% |
| 2002-12-31 | $-4.65 Million | $-1.28 Million | 0.275x | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more